Marvin A. Soriano-Ursua

Dr. Marvin A. Soriano-Ursua

Physiology, Research & Posgraduate Section, Instituto Politécnico Nacional, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2024 in Chemical Reviews
Verified
Journal Article
Closed access
RGR. Justin Grams
R. Justin Grams
WSWebster L. Santos
Webster L. Santos
ISIon Romulus Scorei
Ion Romulus Scorei
AAAntonio Abad-García
Antonio Abad-García
CRCarol Ann Rosenblum
Carol Ann Rosenblum
Marvin A. Soriano-UrsuaMarvin A. Soriano-Ursua
Marvin A. Soriano-Ursua

24 January 2014 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
Marvin A. Soriano-UrsuaMarvin A. Soriano-Ursua
Marvin A. Soriano-Ursua
BDBhaskar C Das
Bhaskar C Das
JTJosé G Trujillo-Ferrara
José G Trujillo-Ferrara
Although the medicinal use of boron-containing compounds (BCCs) had long been limited to antiseptics, in the last few decades, these compounds have been used as antibiotics or chemotherapeutic agents. In the last few years, boron has been included in the moieties of many known drugs to improve their capacity in binding to their respective target receptors. The current review focuses on research and patent literature of the last decade related to the development of BCCs as preventive, diagnostic and therapeutic tools. It explores the possible mechanisms of action of these compounds as well as the advantageous features of their structure and chemico-pharmacological properties. Although uncertainties exist about the mechanism of action of BCCs, increasing evidence about their toxicological profile strongly suggests that many can be safely administered to humans. Even stronger evidence exists regarding the capacity of BCCs to reach multiple targets that are involved in the treatment of common diseases. It seems fair to say that some BCCs will reach the market for medicinal use in the near future, not only for targeting microbial or neoplastic systems but also for acting on cell-signaling processes involved in many other disorders.

22 September 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MFMaría Guadalupe Frías-De-León
María Guadalupe Frías-De-León
RHRigoberto Hernandez-Castro
Rigoberto Hernandez-Castro
ECEsther Conde-Cuevas
Esther Conde-Cuevas
ICItzel Hayde García Coronel
Itzel Hayde García Coronel
VVVíctor Alfonso Vázquez-Aceituno
Víctor Alfonso Vázquez-Aceituno
Erick Martínez HerreraErick Martínez Herrera
Erick Martínez Herrera
In recent years, a progressive increase in the incidence of invasive fungal infections (IFIs) caused by Candida glabrata has been observed. The objective of this literature review was to study the epidemiology, drug resistance, and virulence factors associated with the C. glabrata complex. For this purpose, a systematic review (January 2001–February 2021) was conducted on the PubMed, Scielo, and Cochrane search engines with the following terms: “C. glabrata complex (C. glabrata sensu stricto, C. nivariensis, C. bracarensis)” associated with “pathogenicity” or “epidemiology” or “antibiotics resistance” or “virulence factors” with language restrictions of English and Spanish. One hundred and ninety-nine articles were found during the search. Various mechanisms of drug resistance to azoles, polyenes, and echinocandins were found for the C. glabrata complex, depending on the geographical region. Among the mechanisms found are the overexpression of drug transporters, gene mutations that alter thermotolerance, the generation of hypervirulence due to increased adhesion factors, and modifications in vital enzymes that produce cell wall proteins that prevent the activity of drugs designed for its inhibition. In addition, it was observed that the C. glabrata complex has virulence factors such as the production of proteases, phospholipases, and hemolysins, and the formation of biofilms that allows the complex to evade the host immune response and generate fungal resistance. Because of this, the C. glabrata complex possesses a perfect pathogenetic combination for the invasion of the immunocompromised host.

1 September 2016 in Toxicology Letters
Verified
Journal Article
Closed access
EFEunice D. Farfán-García
Eunice D. Farfán-García
NCN.T. Castillo-Mendieta
N.T. Castillo-Mendieta
FCF.J. Ciprés-Flores
F.J. Ciprés-Flores
IPItzia I. Padilla-Martinez
Itzia I. Padilla-Martinez
JTJ.G. Trujillo-Ferrara
J.G. Trujillo-Ferrara
Marvin A. Soriano-UrsuaMarvin A. Soriano-Ursua
Marvin A. Soriano-Ursua

1 January 2014 in NeuroToxicology
Verified
Journal Article
Closed access
Marvin A. Soriano-UrsuaMarvin A. Soriano-Ursua
Marvin A. Soriano-Ursua
EFEunice D. Farfán-García
Eunice D. Farfán-García
YLYessica López-Cabrera
Yessica López-Cabrera
EQEnrique Querejeta
Enrique Querejeta
JTJosé G. Trujillo-Ferrara
José G. Trujillo-Ferrara

14 May 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
Nancy Vargas MendozaNancy Vargas Mendoza
Nancy Vargas Mendoza
AMAngel Morales-González
Angel Morales-González
MMMauricio Morales-Martínez
Mauricio Morales-Martínez
Marvin A. Soriano-UrsuaMarvin A. Soriano-Ursua
Marvin A. Soriano-Ursua
LDLuis Delgado-Olivares
Luis Delgado-Olivares
JMJose A. Morales-González
Jose A. Morales-González
Silymarin (SM) is a mixture of flavolignans extracted from the seeds of species derived from Silybum marianum, commonly known as milk thistle or St. Mary’sthistle. These species have been widely used in the treatment of liver disorders in traditional medicine since ancient times. Several properties had been attributed to the major SM flavolignans components, identified as silybin, isosilybin, silychristin, isosilychristin, and silydianin. Previous research reported antioxidant and protective activities, which are probably related to the activation of the nuclear factor erythroid 2 (NFE2)-related factor 2 (Nrf2), known as a master regulator of the cytoprotector response. Nrf2 is a redox-sensitive nuclear transcription factor able to induce the downstream-associated genes. The disruption of Nrf2 signaling has been associated with different pathological conditions. Some identified phytochemicals from SM had shown to participate in the Nrf2 signaling pathway; in particular, they have been suggested as activators that disrupt interactions in the Keap1-Nrf2 system, but also as antioxidants or with additional actions regarding Nrf2 regulation. Thus, the study of these molecules makes them appear attractive as novel targets for the treatment or prevention of several diseases.